Breast cancer survivors
Men with breast cancer
People with a genetic mutation linked to cancer risk
Triple negative breast cancer
Women under 45
Women over 45
The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)
|At a glance||Guidelines|
|Findings||Questions for your doctor|
|Media||Resources and references|
approval of the immunotherapy drug Tecentriq for treatment of some advanced triple-negative breast cancers.
On March 8, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval of atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for advanced triple-negative breast cancer. Tecentriq is the first drug known as an "immune checkpoint inhibitor" approved for breast cancer.
Atezolizumab (Tecentriq) is a type of immunotherapy and nab-paclitaxiel (Abraxane) is a type of chemotherapy. The FDA approved the combination of these two drugs as a first line treatment for locally advanced or metastatic triple-negative breast cancer.
Tecentriq is approved for people whose breast cancers express “programmed death-ligand 1” (PD-L1), a protein that may help cancers avoid detection by the immune system. At the same time, the FDA also approved a tumor test, a companion diagnostic test called VENTANA PD-L1 (SP142). This test looks for expression of PD-L1 in cancers and is used to predict which tumors will respond to Tecentriq.
In the clinical trial, patients who received Tecentriq and Abraxane had progression free survival of 7.5 months compared to 5.5 months among patients who received Abraxane without Tecentriq.
Among patients with PD-LI-positive tumors, the median progression free survival was 7.5 months and 5.0 months respectively. Patients who had PD-L1 positive tumors and who received Tecentriq and Abraxane survived about 10 months longer than patients who did not receive Tecentriq.
As with most cancer medicines, the combination of Tecentriq and Abraxane may cause side effects.
The most common side effects were:
35% of the breast cancer patients treated with Tecentriq and Abraxane had severe side effects compared to 30% who had only Abraxane. Severe side effects include inflammation of the lung and liver (13%).
If you’ve been diagnosed with locally advanced or metastatic triple-negative breast cancer, you may want to talk to your doctor about PD-L1 testing of your breast cancer and whether the Tecentriq plus Abraxane treatment combination is right for you.
It’s important to know that Tecentriq did not work for all patients with advanced breast cancer. On average, patients who received Tecentriq had 2 ½ months longer “progression-free survival” than patients who did not receive Tecentriq. On average, patients who received Tecentriq survived 10 months longer than patients who did not receive Tecentriq. Patients who received Tecentriq were more likely to have serious side effects.
Share your thoughts on this XRAYS article by taking our brief survey.
The National Comprehensive Cancer Network (NCCN) is a national panel of experts that create guidelines for cancer treatment. NCCN breast cancer guidelines recommend the following biomarker testing for people with metastatic breast cancer:
The following are a few of the larger, multi-center clinical trials studying immunotherapy drugs for patients with metastatic breast cancer.
NCT03424005: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) is a Phase 2 study enrolling patients with metastatic, triple-negative breast cancer.
NCT03674827: A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC is a Phase 1 study enrolling patients with metastatic, triple-negative breast cancer.
NCT01174121: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer is a Phase 2 study enrolling patients with metastatic cancers (including breast cancer). Patients must have had no response or progression after two lines of treatment. Patients with limited number of brain metastases are eligible.
There are many additional clinical trials in the United States looking at immunotherapy agents alone or in combination with other agents for treating metastatic breast cancer. To search for additional studies, you can visit FORCE's Research Study Search Tool, Clinicaltrials.gov, or Breastcancertrials.org.
Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancers. TNBC is associated with earlier age of onset, aggressive clinical treatments, and a poorer prognosis compared to hormone receptor- and HER2-positive breast cancers. Given the lack of effective treatments for TNBC, researchers have focused on increasing the therapeutic options for TNBC patients.
The immune system has a key influences on the course of TNBC. Clinical trials have sought to better understand and define the role of immune checkpoint inhibitors as a treatment for TNBC. (Immune system checkpoint inhibitors are drugs that prevent malignant cells from evading the immune system). The culmination of these studies was the phase III IMpassion 130 trial. The iMpassion 130 trial showed an overall survival benefit in patients with advanced TNBC who were treated with the immune checkpoint inhibitor atezolizumab in combination with chemotherapy compared to chemotherapy alone.
This XRAYS review provides an update on research that we first covered in 2017.
Whether the combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) compared to nab-paclitaxel alone increased progression-free survival in patients with locally advanced or metastatic TNBC. Progression-free survival is the period when a cancer doesn’t grow.
Patients with untreated metastatic TNBC who participated in the IMpassion130 trial were randomly assigned to receive atezolizumab plus nab-paclitaxel (451 patients) or placebo plus nab-paclitaxel (452 patients). Patients continued their treatment regimens until their disease progressed or an unacceptable level of side effects occurred. Median follow-up timewas 12.9 months.
The two primary trial goals were to determine progression-free survival (the time before tumors grew) in the population treated with atezolizumab and PD-L1-positive subgroup, and overall survival (the time before death) in the population treated with atezolizumab. If the findings related to overall survival were significant, they would then look at the impact of this treatment on the overall survival in the PD-L1-positive subgroup.
Patients who received the combination therapy showed a clinically meaningful median PFS of 7.2 months compared to 5.5 months with chemotherapy alone. One-year progression-free survival rates were 29% and 16% respectively. Among patients with PD-LI-positive tumors, median progression-free survival was 7.5 months and 5.0 months respectively.
Median overall survival was 21.3 months with combination therapy and 17.6 months with nab-paclitaxel alone. A positive overall survival outcome was achieved only in PD-L1-positve TNBC patients. In these patients, median overall survival was 25.0 months compared to 15.5 months for patients with PD-L1-negative tumors.
Almost 16% of patients who received the combination therapy had to stop treatment due to adverse effects, compared to 8.2% of those receiving nab-paclitaxel alone.
The results of IMpassion130 offer hope for immunotherapy as effective treatment of metastatic TNBC. However, researchers raised a number of questions including which tumors should be tested for PD-L1 expression, whether nab-paclitaxel is the best chemotherapy to be used with atezolizumab, and whether atezolizumab alone may be best for some patients.
Treatment with atezolizumab plus nab-paclitaxel increased progression-free survival in patients with metastatic TNBC whose tumors were PD-L1-positive.
Share your thoughts on this XRAYS article by taking our brief survey.